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Abstract
Background:  The HIV-1 Env glycoprotein mediates virus entry by catalyzing direct fusion
between the virion membrane and the target cell plasma membrane. Env is composed of two
subunits: gp120, which binds to CD4 and the coreceptor, and gp41, which is triggered upon
coreceptor binding to promote the membrane fusion reaction. Env on the surface of infected cells
is a trimer consisting of three gp120/gp41 homo-dimeric protomers. An emerging question
concerns cooperative interactions between the protomers in the trimer, and possible implications
for Env function.
Results: We extended studies on cooperative subunit interactions within the HIV-1 Env trimer,
using analysis of functional complementation between coexpressed inactive variants harboring
different functional deficiencies. In assays of Env-mediated cell fusion, complementation was
observed between variants with a wide range of defects in both the gp120 and gp41 subunits. The
former included gp120 subunits mutated in the CD4 binding site or incapable of coreceptor
interaction due either to mismatched specificity or V3 loop mutation. Defective gp41 variants
included point mutations at different residues within the fusion peptide or heptad repeat regions,
as well as constructs with modifications or deletions of the membrane proximal tryptophan-rich
region or the transmembrane domain. Complementation required the defective variants to be
coexpressed in the same cell. The observed complementation activities were highly dependent on
the assay system. The most robust activities were obtained with a vaccinia virus-based expression
and reporter gene activation assay for cell fusion. In an alternative system involving Env expression
from integrated provirus, complementation was detected in cell fusion assays, but not in virus
particle entry assays.
Conclusion: Our results indicate that Env function does not require every subunit in the trimer
to be competent for all essential activities. Through cross-talk between subunits, the functional
determinants on one defective protomer can cooperatively interact to trigger the functional
determinants on an adjacent protomer(s) harboring a different defect, leading to fusion.
Cooperative subunit interaction is a general feature of the Env trimer, based on complementation
activities observed for a highly diverse range of functional defects.
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Background
The envelope glycoprotein (Env) of human immunodefi-
ciency virus type 1 (HIV-1) promotes virus entry by cata-
lyzing direct fusion between the virion membrane and the
target cell plasma membrane; similarly, Env-expressing
cells can fuse with target cells to form multinucleated
giant cells (syncytia). Env is synthesized as a gp160 pre-
cursor protein that assembles into homo-trimeric com-
plexes in the endoplasmic reticulum. During transport
through the secretory pathway, gp160 is cleaved in the
trans-Golgi network by a furin-like protease(s) to yield the
external gp120 subunit noncovalently associated with the
gp41 transmembrane subunit (derived from the N- and C-
regions of gp160, respectively) [1]. The functional Env
spike on mature virions of HIV-1 and the related simian
immunodeficiency virus consists of a homo-trimer of
gp120/gp41 hetero-dimers [2].
Env-mediated fusion involves a strict division of labor
between the two subunits: gp120 is responsible for
sequential binding to specific target cell receptors, first to
CD4 and then to the coreceptor (a specific chemokine
receptor, typically CCR5 or CXCR4); receptor binding
then triggers gp41 to promote membrane fusion. These
steps involve a tightly orchestrated series of conforma-
tional changes in both Env subunits that drive the fusion
process. The emerging understanding of the complexities
of HIV Env/receptor interactions and the subsequent
events leading to fusion/entry have been the central focus
of numerous review articles over the past decade [3-8]. X-
ray crystallographic analyses of gp120 from HIV-1 [9] and
the closely related simian immunodeficiency virus [10]
have revealed that CD4 binding induces a profound rear-
rangement of the relatively disordered gp120 subunit to
create a new surface consisting of four anti-parallel beta
strands derived from discontinuous regions of the linear
sequence; this highly conserved "bridging sheet", which is
not present in the unliganded pre-CD4-bound state, is
directly involved in binding to coreceptor [11] in conjunc-
tion with the third variable loop (V3) of gp120, which
determines coreceptor specificity [12,13]. Binding of
gp120 to coreceptor then triggers the fusogenic activity of
gp41 in a process believed to involve insertion of the gp41
N-terminal fusion peptide (FP) into the target cell plasma
membrane [14,15]. Detailed structural information is not
yet available for the native state of gp41, but the structure
of the final post-fusion state has been determined to be a
trimer of hairpins in the form of a six-helix coiled-coil
bundle [16-18]. A transient intermediate conformation is
thought to exist in which the gp41 subunits adopt an
extended triple-helix coiled-coil with the N-terminal FPs
inserted into the target cell membrane. The heptad repeat
(HR) segments near the external C-terminal region (HR2)
then fold to insert in anti-parallel fashion into the grooves
formed by the cluster of the three N-terminal heptad
repeat (HR1) segments; the resulting formation of a 6-
helix bundle brings the virion and target cell plasma
membranes together, and provides the driving force for
membrane fusion underlying HIV entry. The molecular
complexity of the HIV entry process presents a variety of
targets for novel antiviral agents [19-22]; the T-20 peptide
(enfuvirtide, Fuzeon) targeting the gp41 intermediate
conformation is the first-in-class HIV-1 fusion inhibitor
[23], and the recently approved maraviroc is the first-in-
class inhibitor that binds to the CCR5 coreceptor and
blocks the gp120 interaction [24].
While each gp120/gp41 hetero-dimeric complex contains
all the determinants required for fusion, it is possible that
molecular interactions between complexes within the
trimer influence Env function. In a previous study we used
a quantitative vaccinia expression-based cell fusion assay
to demonstrate that individual subunits within the Env
trimer can interact cooperatively during fusion [25]. By
coexpressing Env proteins with defects in different essen-
tial determinants, we found that functional complemen-
tation could occur between subunits within a mixed
trimer. In the present report, we show that subunit com-
plementation is a general capacity of the HIV-1 Env
trimer, though its efficiency and detectability are depend-
ent on the particular defective variants examined and the
assay systems employed. The results are discussed in terms
of potential biological implications for Env function and
HIV neutralization.
Methods
Construction and expression of Env variants
For vaccinia virus expression-based cell fusion assays,
HIV-1 Envs were transiently expressed from pSC59-based
plasmids under control of a strong synthetic vaccinia virus
early/late promoter [26]. Previously described plasmids
[27,28] were used to express wild-type Envs from the fol-
lowing HIV-1 strains: LAI [29] (LAV isolate, unless indi-
cated otherwise), plasmid pCB-41; SF162, plasmid pCB-
32; Ba-L, plasmid pCB-43, and CM235, plasmid pCB-52.
In addition, a Kpn I-Xho I fragment encoding wild-type
YU-2 Env was substituted into a variant of pCB-41 con-
taining a unique Xho I site at the 3' end of Env (pKS-9) to
create the plasmid pKS-10. As a negative control, an
uncleaveable (Unc) mutant form of LAI (IIIB isolate) was
used (plasmid pCB-16).
Plasmids pKS-3 and pKS-4 [25] encode mutants of LAI
Env (HXB2 isolate) with a D368R substitution in the CD4
binding site (BS) of gp120 that abolishes CD4 binding
(LAI-BS) and a Leu to Arg substitution at residue 26 of the
gp41 N-terminal fusion peptide (LAI-FP26) [30], respec-
tively. Additional site-directed mutations were introduced
(QuikChange kit, Stratagene, La Jolla, CA) into pCB-41
encoding wild-type LAI Env resulting in the following
plasmid constructs. See Fig. 1 Legend for descriptions: FP
mutants LAI-FP2 (plasmid pKS-13) and LAI-FP9 (plasmidRetrovirology 2009, 6:75 http://www.retrovirology.com/content/6/1/75
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pKS-14); heptad repeat mutants LAI-HR1a (plasmid pKS-
15) and LAI-HR1e (plasmid pKS-16); V3 loop mutant
LAI-V3 (plasmid pKS-17). A Kpn I-Bam HI fragment
encoding the LAI-Δ665-856 mutant, previously referred to
as Δ192 [31], was substituted into a variant of pCB-41
(pKS-8) in which a Bam HI site upstream of the promoter
had been destroyed by cutting and then filling in with T4
DNA polymerase; the resulting plasmid was pKS-18. Kpn
I-Xho I fragments encoding the mutants LAI-HT-1 [32],
LAI-HT-2 [32], and LAI-Δ665-682 [33,34] were substi-
tuted into the plasmid pKS-8 to create the plasmids pKS-
19, pKS-20, pKS-21, and pKS-22, respectively. Previous
studies indicate that each of these variants is capable of
Env processing (except for Unc), surface expression
(except for LAI-Δ665-856, which is secreted), and CD4
binding (except for LAI-BS) [25,30,32-34].
For MAGI cell HIV infectivity assays, virus was expressed
from the pNL4-3 proviral clone [35] encoding wild-type
LAI Env (LAV isolate). pNL4-3 containing a frame-shift
mutation at the Nhe I site within Env (pNL4-3Δenv) [33]
was used as a negative control. Nhe I-Bam HI fragments
encoding the LAI-FP26 and LAI-BS mutants [25] were sub-
cloned into pNL4-3 to create pKS-11 (encoding NL4.3-
FP26) and pKS-12 (encoding NL4.3-BS), respectively. The
phenotype for each construct, both when expressed alone
and in complementation experiments, was confirmed
using two independent plasmid clones constructed in par-
allel.
Vaccinia virus-based cell fusion assay
Env-mediated cell fusion activity was measured using a
quantitative vaccinia-based reporter gene assay as
described previously [36,37]. Each vaccinia virus was used
at a multiplicity of infection of 10. Target cells were pre-
pared by co-infecting NIH 3T3 cells with vaccinia virus
recombinant vCB21R-LacZ containing the E. coli lacZ
reporter gene linked to the T7 promotor [38], plus vac-
cinia recombinants encoding the following cDNAs linked
to vaccinia early/late promoters: CD4, vCB-3 [39] and the
designated coreceptor CCR5, vHC-1 [40] or CXCR4,
vCBYF1-fusin [41]. Effector cells were prepared by trans-
fecting HeLa cells with the above-described plasmids con-
taining the Env genes linked to a strong synthetic vaccinia
early/late promoter and infecting with vaccinia recom-
binant vP11T7gene1 encoding bacteriophage T7 RNA
polymerase [42]. Transfection was performed with
DOTAP (Boehringer Mannheim, Indianapolis, IN); the
total amount of DNA was held constant at 5 μg DNA per
25 cm2 flask, in both single-transfection and cotransfec-
tion experiments. Effector and target cells were incubated
overnight at 31°C to allow expression of the recombinant
proteins. After these cells were washed by centrifugation,
they were mixed in equal numbers in duplicate wells of a
96-well plate (2 × 105 of each per well) and incubated for
2.5 hr at 37°C. Fusion reactions were terminated by addi-
tion of nonidet-P40 (0.5% final) and quantified by spec-
trophotometric measurement of β-galactosidase activity
as described previously [36]. For each data point, error
bars indicate the standard errors of the mean of duplicate
samples; in cases where error bars appear to be absent, the
data points were so close that error bars are not visible. All
experiments were repeated at least twice; representative
data are shown for each experiment.
MAGI cell assays for cell fusion and virus entry
HIV-1 entry and Env-mediated cell fusion in the context of
HIV-1 provirus expression were measured using the HeLa-
CD4/LTR-β-gal (MAGI) indicator target cell line [43],
which was obtained from the NIH AIDS Research and Ref-
erence Reagent Program (originally contributed by M.
Emerman). BS-C-1 cells plated at 3 × 105 per well in 6-well
Mutations in HIV-1 Env Figure 1
Mutations in HIV-1 Env. A schematic representation of 
HIV-1 Env. Functional and structural domains within the 
gp120 and gp41 subunits are labeled at the top: V3 loop (3rd 
variable loop), CD4 BS (CD4 binding site), FP (fusion pep-
tide), TRR (tryptophan-rich region), TM (transmembrane 
domain). For various inactivating mutants in the LAI Env (des-
ignations encircled), the approximate locations of specific 
point mutants are indicated underneath, and the deletion 
mutants are indicated on the right. The specific point muta-
tions are: V3 (R320G in the conserved GPGR motif at the tip 
of the V3 loop); BS (D368R within the CD4 binding site); var-
ious positions in the fusion peptide including FP2 (Val→Glu), 
FP9 (Leu→Arg) and FP26 (Leu→Arg); heptad repeat muta-
tions HR1e (V570R) and HR1a (I573P). HT-1 and HT-2 are 
chimeric LAI Env/Thy-1.1 glycoproteins that are membrane-
associated via a glycosyl-phosphatidylinositol (GPI) anchor. 
HT-1 contains the gp41 ectodomain minus the tryptophan-
rich region (K665 through I682), whereas HT-2 contains the 
entire gp41 ectodomain; both constructs have 22 intervening 
amino acid residues from the C-terminus of Thy1.1. The 
Δ665-682 construct has a selective deletion of the TRR 
(K665 through I682) and the Δ665-856 construct has an 
introduced premature stop codon that results in deletion of 
the C-terminal 192 aa of Env, including the TM and cytoplas-
mic domains. See Methods for construction and references.
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FP Cleavage CD4 BS
NH2 COOH
V3 loop TRR
ENV
V3
FP26
BS
FP9
FP2 HR1e HR1a
HR1 HR2 NH2 HT-2
HR1 HR2 NH2 665-856Retrovirology 2009, 6:75 http://www.retrovirology.com/content/6/1/75
Page 4 of 11
(page number not for citation purposes)
plates the previous day were transfected (or cotransfected)
with the designated pNL4-3-based proviral construct(s)
using FuGENE 6 (Boehringer Mannheim, Indianapolis,
IN) according to the manufacturer's protocol. The next
day, cells were washed and given fresh media (2 ml per
well) containing 10 mM HEPES. Three days post-transfec-
tion, the supernatants were removed, filtered through a
0.45 μm filter to remove cellular debris, and stored at 4°C.
For cell fusion assays, the cells were trypsinized, washed,
mixed 1:10 with MAGI cells, and replated in duplicate at
1 × 105 total cells per well of a 24-well plate. Cells were
allowed to fuse overnight at 37°C and were then stained
with X-gal. Cell fusion was quantitated by counting the
total number of blue multi-nucleated syncytia per well
with the aid of a grid. For the virus entry assays, p24 levels
in the filtered supernatants were quantitated using the
HIV-1 p24 Antigen Assay (Coulter), and supernatant vol-
umes were normalized accordingly. MAGI cells were
infected in duplicate with 300 μl of filtered supernatant
per well of a 24-well plate and stained with X-gal 48 hrs
post-infection. Virus entry was quantitated by counting
the total number of blue foci per well. For complementa-
tion pairs, supernatants containing up to 2.35 ng of p24
per well were used (equivalent to 628 infectious units for
wild-type). This corresponds to approximately 15–20% of
the total supernatant from the cells. For each data point,
the standard errors of the mean of duplicate samples are
shown.
Results
To test the ability of fusion-inactive Env subunits to func-
tionally complement one another in the context of mixed
Env trimers, we first employed a vaccinia-based quantita-
tive cell fusion assay system wherein fusion between effec-
tor cells expressing Env and target cells expressing the
necessary receptors leads to reporter gene activation (β-
galactosidase production) [36,37]. We examined comple-
mentation between variants in gp120 that were inactive
due to inability to interact with CD4 (CD4 BS mutation)
or coreceptor (mismatched specificity, or mutation in the
V3 loop), as well as variants in gp41 with mutations at dif-
ferent points within the FP and HR1 regions, as well as
modifications of the membrane proximal tryptophan-rich
region (TRR) and the transmembrane (TM) domain (Fig.
1). Throughout these studies, target cells lacking corecep-
tor served as negative controls; where indicated, an
uncleaveable mutant Env (Unc) containing a mutation in
the gp120/gp41 cleavage site provided an additional neg-
ative control.
Complementation by Env subunits from HIV-1 primary 
isolates of different genetic subtypes
Previously we demonstrated complementation between
Env constructs from two HIV-1 strains that were highly
laboratory-adapted and both clade B: LAI (X4, i.e. CXCR4-
specific) and SF162 (R5, i.e. CCR5-specific) [25]. To deter-
mine whether complementation potential is a more gen-
eral property of HIV-1 Envs, we analyzed the relative
complementation efficiencies of an LAI Env mutant con-
taining a defective FP (LAI-FP26) with Envs from diverse
R5 isolates in a CXCR4-dependent cell fusion assay. When
tested alone under these conditions, wild type LAI showed
potent activity whereas the LAI-FP26 mutant and all four
wild type R5 Envs were non-fusogenic (Fig. 2A, top sec-
tion). In coexpression experiments that enabled mixed
trimer formation, complementation of LAI-FP26 with the
R5 Envs occurred not only with SF162 as shown previ-
ously, but also with the laboratory-adapted Ba-L strain
(clade B) and the primary YU-2 (clade B) and CM235
(CRF01_AE recombinant) isolates (Fig. 2A, middle sec-
tion). The differences in the relative complementation
efficiencies of the various Envs correlated roughly with
their relative intrinsic fusogenicities in a CCR5-dependent
assay (Fig. 2B).
Complementation by Env subunits containing a 
mutationally inactivated V3 loop
Our previous results [25] coupled with the data above
demonstrate that an Env with a mutational defect in gp41
can complement an Env containing a gp120 subunit inca-
pable of interacting with coreceptor due to mismatched
coreceptor specificity. We wished to extend this finding by
testing a gp120 subunit rendered inherently defective for
coreceptor interaction by site-directed mutation. The V3
loop, though highly variable, contains a conserved β-turn
motif at its crown (typically GPGR or GPGQ) that is essen-
tial for coreceptor binding activity [12,13]. We analyzed a
point mutant (LAI-V3) containing a G in place of the R
residue in the GPGR motif, which has been shown previ-
ously to abolish fusogenicity [44]. Our results demon-
strate that the fusion-defective LAI-V3 was able to
complement LAI-FP26 (Fig. 2A, bottom section). The
fusion activity was in the same range observed for the
coreceptor-mismatched Envs (Fig. 2A, middle section),
indicating that complementation efficiency was not lim-
ited by structural incompatibilities between Envs from
these different strains.
Previously we demonstrated complementation between
Envs containing different nonfunctional gp120 subunits
within a mixed trimer; functional mixed trimers were
formed when LAI-BS (defective for CD4 binding) was
coexpressed with wild-type SF162 (incapable of corecep-
tor interaction in a CXCR4-specific assay) [25]. To extend
this finding we tested the ability of LAI-BS to complement
LAI-V3, i.e. gp120 subunits incapable of interacting with
CD4 and coreceptor, respectively (Fig. 3). The efficiency
was similar to that observed for complementation
between LAI-BS and SF162, again indicating that there
were minimal structural incompatibilities in mixed trim-
ers between these two strains. As reported previously [25],
these examples of complementation between Envs withRetrovirology 2009, 6:75 http://www.retrovirology.com/content/6/1/75
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distinct gp120 receptor binding deficiencies were some-
what less active than complementation between Envs
containing a defective gp120 and a defective gp41 (LAI-BS
+ LAI-FP26) (Fig. 3). As expected, no complementation
was observed upon coexpression of LAI-V3 with SF162,
since the gp120 from neither Env is capable of function-
ing with the CXCR4 coreceptor.
Varying complementation efficiencies of different point 
mutations within the gp41 FP
Our previously described data and the experiments above
demonstrated functional complementation of a particular
gp41 FP mutation, i.e. substitution of Arg for Leu at the
26th position from the gp41 N-terminus (LAI-FP26). To
extend these analyses, we analyzed two additional FP
mutations previously shown by others to abolish
fusogenic activity without affecting Env processing or
CD4 binding [30]: LAI-FP2 substitutes Glu for Val at the
2nd position of the FP, and LAI-FP9 substitutes Arg for Leu
at the 9th position (Fig. 1). The LAI-FP2 mutant has been
shown to dominantly interfere with cell fusion when
coexpressed with wild-type Env, whereas the LAI-FP9
mutant reduced fusion two-fold and the LAI-FP26 mutant
had no negative effect when coexpressed with wild-type
Env [45]. The results of complementation experiments
with these gp41 FP mutations are shown in Fig. 4. Con-
sistent with previous reports, each mutation alone
strongly impaired cell fusion activity compared to wild
type (top sections in Figs. 4A–C). The relative efficiencies
of complementation, FP26 > FP9 > FP2 was observed
whether the complementation partner was LAI-BS (Fig.
4A), LAI-V3 (Fig. 4B), or SF162 (wt) (Fig. 4C).
Complementation with gp41 subunits lacking the normal 
membrane anchoring and membrane proximal external 
regions
Highly conserved regions close to the membrane are
known to be critical for Env function, including the 22
amino acid TM domain that anchors Env to the surface of
virions and infected cells, and the membrane-proximal
external region, generally defined as the last 24 C-terminal
residues of the gp41 ectodomain (L660 – K683) [15]. This
Complementation with laboratory-adapted and primary Envs  from different clades Figure 2
Complementation with laboratory-adapted and pri-
mary Envs from different clades. The vaccinia system 
was employed to assay cell fusion between effector cells 
expressing Envs and target cells expressing CD4 either with 
(filled bars) or without (open bars) the indicated coreceptor. 
A) CXCR4-dependent fusion. Effector cells expressed the 
indicated Envs either individually (top section) or in combina-
tion with LAI-FP26 (middle section). Effector cells expressed 
LAI-V3 individually or in combination with LAI-FP26 (bottom 
section). B) CCR5-dependent fusion. The indicated wt Envs 
were assayed for their intrinsic fusogenicity with target cells 
expressing CD4 and CCR5.
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LAI-FP26 + Complementation between gp120 variants Figure 3
Complementation between gp120 variants. The vac-
cinia system was employed to assay cell fusion between effec-
tor cells expressing Envs and target cells expressing CD4 
either with (filled bars) or without (open bars) CXCR4. 
Effector cells expressed the indicated Envs either individually 
(top section) or in combination with the indicated gp120-
defective Envs LAI-BS or LAI-V3 (bottom section).
Cell Fusion Activity ( -gal, OD/min X 1000) 
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region contains the TRR (defined here as K665 – K683) and
contains or overlaps the epitopes for the broadly neutral-
izing 2F5 and 4E10 monoclonal antibodies. We tested five
previously described defective mutants in this gp41 region
for their ability to support complementation. HT-1 and
HT-2 are chimeric LAI Env/Thy-1.1 glycoproteins that are
membrane-associated via a glycosyl-phosphatidylinositol
(GPI) anchor. HT-1 contains the gp41 ectodomain minus
the tryptophan-rich region whereas HT-2 contains the
entire gp41 ectodomain; both constructs have 22 inter-
vening amino acid residues derived from the C-terminus
of Thy1.1 [32]. HG-1 is analogous to HT-1 except that a
minimal GPI attachment signal has been used without the
intervening Thy-1.1 residues (K. Salzwedel and E. Hunter,
unpublished data). LAI-Δ665-856 contains a stop codon
in place of the Lys at position 665, resulting in deletion of
192 amino acids from the C-terminus, including the
entire tryptophan-rich, TM, and cytoplasmic domains;
this protein is secreted into the medium [31]. Finally, LAI-
Δ665-682 contains an 18-amino acid deletion of the tryp-
tophan-rich region (K665 – I682) [33,34].
The results of complementation experiments with these
mutants are shown in Fig. 5A. Each of the fusion-defective
GPI-anchored Envs was capable of complementing LAI-
BS. Perhaps surprisingly, even the truncated non-
anchored LAI-Δ665-856 Env was able to complement the
full-length LAI-BS665-856 mutant, with comparable or
higher efficiency compared to the GPI-anchored con-
structs.
Complementation with gp41 subunits containing heptad 
repeat mutations
Two previously characterized point mutations within the
N-terminal heptad repeat region (HR1) of the gp41 ecto-
domain (Fig. 1) were analyzed for complementation, i.e.
substitution of Pro for Ile at residue 573 at the "a" posi-
tion within the HR1 heptad repeat motif (LAI-HR1a) and
Arg for Val at residue 570 at the "e" position within the
HR1 heptad repeat (LAI-HR1e). The LAI-HR1a mutation
has been shown previously to disrupt self-association of
HR1 to form the trimeric coiled-coil pre-hairpin interme-
diate structure [46] and the LAI-HR1e mutation is sus-
pected to block association of HR2 with the HR1 trimer to
form the 6-helix coiled-coil hairpin structure [47]. Inter-
estingly, each of these mutants displayed some comple-
mentation activity with LAI-BS Fig. 5B). However the
efficiency was relatively low, and no significant comple-
mentation by these mutants was observed with Envs
defective in CXCR4 interaction (LAI-V3 and SF162 wt,
data not shown).
Complementation requires coexpression of Env mutants 
within the same cell
The observed complementation activities involved coex-
pression of two distinct nonfusogenic Env variants within
the same cell. Although in our previous study [25] we ver-
ified the formation of mixed trimers between the two var-
iants, we could not rule out the possibility that the
complementation activity was due to cooperative interac-
tions between nonfusogenic homo-trimers of each vari-
ant. While this seemed an unlikely explanation, it has
been reported that cell fusion can occur when CD4 and
coreceptor are expressed on separate target cells [48]. To
determine whether this might also be true for Env trimers
Complementation with Envs containing point mutations in  the gp41 fusion peptide Figure 4
Complementation with Envs containing point muta-
tions in the gp41 fusion peptide. The vaccinia system was 
employed to assay cell fusion between effector cells express-
ing Envs and target cells expressing CD4 either with (filled 
bars) or without (open bars) CXCR4. Within each section, 
effector cells expressed the indicated Envs either individually 
(top section) or in combination with the indicated nonfunc-
tional Envs (bottom section): A. LAV-BS, B. LAV-B3, C. 
SF162 (wt).
A.
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expressed on separate cells, we expressed LAI-BS and LAI-
FP26 in separate effector cells and asked whether mixing
the two cell populations with target cells could result in
fusion. As shown in Fig. 6, fusion was detected only when
the constructs were cotransfected into the same effector
cell population, indicating that functional complementa-
tion requires both Env variants to be expressed within the
same cell.
Complementation activity is dependent on the nature of 
the functional assay
The cell fusion assay used in the above experiments
employed vaccinia virus expression technology to pro-
duce Env and CD4 and to provide the reporter gene acti-
vation system for readout. We wished to assess whether
complementation could also be detected in a more bio-
logically relevant situation, i.e. under conditions of HIV-1
proviral expression, using a target cell reporter system
more commonly used to quantitate this process. Further-
more, we asked whether complementation can be
detected not only by measuring Env-mediated cell fusion,
but also virion entry. To address these questions, we
expressed Env from molecular variants of an HIV-1 infec-
tious molecular clone and analyzed both cell fusion and
virus entry using as targets the well studied HeLa-CD4/
LTR-β-gal (MAGI) indicator cell line [43]. Proviruses
encoding the LAI-FP26 and the LAI-BS mutant Envs were
cotransfected into BS-C-1 producer cells. This Env variant
pair was selected because it consistently yielded the high-
est levels of fusion complementation in the vaccinia-
based system. Two alternative assays were then compared.
First, the BSC-1 producer cells were used as effectors and
mixed with MAGI target cells in a cell fusion assay; sec-
ond, filtered supernatants from the BSC-1 producer cells
containing cell-free HIV-1 virions were used to infect
MAGI cells in a parallel virus entry assay. In both cases,
complementation was assessed by counting the number
of blue foci observed upon in situ staining with X-gal. As
shown in Table 1, functional complementation was
detected in the cell fusion assay: cells transfected individ-
ually with either NL4-3-FP26 or NL4-3-BS infectious
molecular clones were fusion-incompetent, whereas cells
cotransfected with both gave significant fusion activity. By
Complementation with Envs containing alterations in the  membrane-spanning domain, the TRR, and HR1 Figure 5
Complementation with Envs containing alterations 
in the membrane-spanning domain, the TRR, and 
HR1. The vaccinia system was employed to assay cell fusion 
between effector cells expressing Envs and target cells 
expressing CD4 either with (filled bars) or without (open 
bars) CXCR4. Within each section, effector cells expressed 
the indicated Envs either individually (top section) or in com-
bination with the nonfunctional LAV-BS (lower section).
LAI-FP26
LAI-FP26
LAI-HR1a
LAI-HR1e
LAI (wt)
LAI-BS
LAI-HR1a
LAI-HR1e
LAI-BS +
Cell Fusion Activity ( -gal, OD/min x 1000)
02 0 4 0 6 0
No coreceptor
CXCR4
B.
A.
Cell Fusion Activity ( -gal, OD/min x 1000)
No coreceptor
CXCR4
0 50 100 150
LAI-BS +
LAI-FP26
LAI (wt)
LAI-BS
LAI-FP26
LAI-HT-1
LAI-HT-2
665-682 LAI-
LAI-HT-1
LAI-HT-2
665-682 LAI-
665-856 LAI-
665-856 LAI-
Complementation requires coexpression of Env mutants  within the same cell Figure 6
Complementation requires coexpression of Env 
mutants within the same cell. The vaccinia system was 
employed to assay cell fusion between effector cells express-
ing Envs and target cells expressing CD4 either with (filled 
bars) or without (open bars) CXCR4. Top section: Effecter 
cells expressing the indicated Envs individually. Bottom sec-
tion: Effector cells either cotransfected with the indicated 
Envs, or infected separated and mixed 1:1.
Unc
LAI (wt)
LAI-BS + LAI-FP26:
cotransfection
LAI-FP26
LAI-BS + LAI-FP26:
separate transfections
LAI-BS
Cell Fusion Activity ( -gal, OD/min x 1000)
0 50 100
No coreceptor
CXCR4Retrovirology 2009, 6:75 http://www.retrovirology.com/content/6/1/75
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contrast, no complementation was observed in the virus
entry assay using the viruses produced from these same
cells (Table 1).
Discussion
The present results extend our earlier findings [25] by
demonstrating that the capacity for functional subunit
complementation is a general feature of the HIV-1 Env
trimer. We interpret our results to reflect cooperative sub-
unit interactions within mixed heterotrimers, consistent
with our previous verification that mixed heterotrimers do
indeed form upon coexpression of different HIV-1 Env
variants, as well as our previous reference to other exam-
ples of mixed trimer formation with glycoproteins from
different enveloped viruses [25]; however we cannot for-
mally exclude the possibility that the observed comple-
mentation activities reflect complex interactions amongst
homo-trimers with different defects expressed on the
same membrane. In the present work, complementation
was observed upon coexpression of Envs from primary as
well as laboratory-adapted HIV-1 strains of different gen-
otypes, and with a wide diversity of defects within both
gp120 and gp41 (Figs. 2, 3, 4, 5). Thus fusion does not
require every gp120 subunit in the trimer to be competent
for CD4 or coreceptor binding, nor every gp41 subunit to
contain a functional fusion peptide, a normal membrane
anchoring region, a native TRR, or a functional HR1
region. We also demonstrate that complementation
requires coexpression of the Env variants in the same cell
(Fig. 6), and provide further evidence (by virtue of com-
plementation between LAI-BS and LAI-V3, Fig. 3) against
the interpretation that the observed complementation
requires reassortment of gp120 and gp41 subunits to form
homo-trimers composed of completely functional gp120/
gp41 protomers.
We interpret complementation as a reflection of coopera-
tive cross-talk between defective protomers within a
mixed trimer, whereby the wild type determinants on one
protomer transmit structural changes to activate wild type
determinants on an adjacent protomer(s), thereby over-
coming defects that are otherwise inactivating in the con-
text of homo-trimers. For example when a CD4 BS mutant
is coexpressed with coreceptor inactive variant, we pro-
pose that CD4 binding to the subunit(s) with functional
BS promotes the conformational changes required for
coreceptor binding, which are then transmitted to an adja-
cent gp120 subunit(s) that can then undergo the essential
coreceptor interaction, thereby triggering activation of the
wild type gp41 subunits. Particularly striking is the wide
range of gp41 mutants capable of complementation when
coexpressed with a nonfunctional gp120 variant. Nearly
all tested displayed some level of activity, the only excep-
tion being LAI-Δ665-682, a normally anchored form con-
taining a deletion of the TRR. The mere absence of the TRR
cannot be the simple explanation, since several constructs
lacking this region did show complementation activity
(HT-1, LAI-Δ665-856). Perhaps misalignment of the LAI-
Δ665-682 mutant with wild type gp41 is not tolerated for
Env function.
Several Env defects have been described in the literature as
"dominant negative", based on their potent functional
suppressive activities when coexpressed with wild type
Env. Mutants in the gp120/gp41 cleavage site, which
alone are completely inactive for fusion and infectivity,
are reported to have strong dominant negative activities
when coexpressed with wild type Env [49,50]. In our pre-
vious studies complementation was not detected with
mixed trimers in which Unc was one of the defective vari-
ants [25]; thus dominant suppression appears to be the
major functional activity for uncleaved Env. However we
show here that this is not the case for all reported domi-
nant negative mutations. Despite the strong inhibitory
activities in fusion and infectivity assays reported for the
FP2 mutation when coexpressed with wild type [45], we
found that the same mutant is still able to complement
fusion activity (albeit at relatively low levels) in mixed
trimers with various non-functional Envs (Fig. 4). In fact
the relative complementation efficiencies of the FP
mutants (FP26 > FP9 > FP2) (Fig. 4) inversely correlated
with their previously described inhibitory effects when
coexpressed with wild type Env (FP2 > FP9 > FP26) [45].
Another example involves the TM domain, for which it
has been reported that substitution of this HIV-1 Env
region with its counterpart from the influenza virus
hemagglutinin glycoprotein results in potent dominant
inhibition [51]. The present studies indicate that this sup-
pressive effect is not due simply to the absence of the
native functional HIV-1 TM region, since we observed
complementation with fusion-defective constructs in
which the normal membrane-spanning domain was
replaced by a GPI anchor, or was completely deleted (Fig.
5A). Thus the complementation analyses help distinguish
Table 1: Complementation analysis of Envs expressed from 
infectious HIV-1 molecular clones in assays of cell fusion and 
virus entry.
No. of blue foci per well
Construct Cell fusion Virus Entry
Mock transfected 0 0
NL4-3 ΔEnv 0 0
NL4-3 (wt) 620 +/- 45 314 +/- 4
NL4-3-FP26 0 0
NL4-3-BS 0 0
NL4-3-FP26 + NL4-3-BS 40 +/- 2 0Retrovirology 2009, 6:75 http://www.retrovirology.com/content/6/1/75
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between a fusion-defective Env variant that exerts a strictly
dominant suppressive activity, vs. others that, though
defective, can permit a low level of functionality as
revealed by the ability of their active determinants to com-
plement when coexpressed with a variant defective in
another function.
Complementation in cell fusion assays was observed not
only with the previously described robust vaccinia-based
expression and reporter system (Figs. 2, 3, 4, 5, 6), but also
with Env expression from an HIV-1 infectious molecular
clone using the MAGI reporter cell line as targets (Table
1). However there were marked variations in complemen-
tation efficiencies depending on the assay system
employed. Thus, for complementation between LAI-BS
and LAI-FP26, the activities in the vaccinia cell fusion sys-
tem ranged from about ~30–50% relative to wild type WT,
consistent with our previous findings [25]; in contrast, the
relative activities were much lower with the infectious
HIV/MAGI system, i.e. only ~6% in the cell fusion assay
and below detection in the virus entry assay (Table 1). We
believe these differences mainly reflect variations in the
robustness of the functional Env-receptor interactions and
the associated reporter gene activation readouts in the dif-
ferent assays, rather than fundamental mechanistic dis-
tinctions. Numerous variables can influence the efficiency
of Env-receptor interactions leading to fusion/entry,
including surface densities of the participating molecules,
gp120 affinities for CD4 and coreceptor, varying receptor
conformations and molecular associations, the biochem-
ical environments of both effector and target membranes
(lipid composition, facilitating or interfering accessory
factors), etc. [52,53]. Similarly for the reporter gene read-
outs, multiple parameters can influence detectability (sig-
nal sensitivity, signal/background ratios, etc.), and
different factors might be limiting for the measured read-
out in alternate assay systems. Thus, while a particular
assay might be quantitative in terms of yielding numeri-
cally reproducible values, such data are not necessarily
proportional to the inherent functional activities of the
particular Env-receptor interactions involved. Therefore,
some assays might reveal weak activities not detected by
others, but might overestimate their relative efficiencies.
Further complicating the quantitative interpretation is the
fact that unlike wild type Env, for which all trimers are
potentially active, the complementation activities result
only from mixed trimers which presumably represent a
subset (theoretically 75%) of the total; moreover upon
cotransfection of two nonfunctional Env variants (A & B),
the relative functionalities of the two possible mixed trim-
ers (AAB and ABB) might be very different. Thus the
reported absence of Env complementation in assays of
both reporter virus entry and cell fusion [54] could reflect
the absence of functional interactions between the partic-
ular mutant Env constructs examined (different from
those tested in this report), or limited sensitivities in the
assays used. Another point worth noting is that our
approach to studying cooperativity within the Env trimer
involved complementation analyses between Env
mutants that were inactive when expressed alone; thus
functional activity was detected despite the presence of a
fusion-impairing determinant in every protomer of the
mixed trimer. It seems reasonable to propose that the con-
tributions of subunit cooperativity to Env function might
be greater with wild type native Env molecules, in which
all subunits are fully functional.
We propose that our inability to detect complementation
in the virus entry assay despite its clear measurement in
the parallel cell fusion assay does not necessarily imply
fundamental differences in the corresponding membrane
fusion mechanisms. Several inter-related factors presuma-
bly contribute to the inability to detect complementation
in the virus entry assay. For one, the density of trimeric
spikes on HIV-1 virions recently observed by cryo-electron
microscopy [55,56] is quite low (<15 trimers per virion,
range ~1–3 dozen). A second point concerns uncertainties
in the trimer stoichiometry required for Env-mediated vir-
ion entry, as indicated by differences in recent effort to fit
experimental data to mathematical models. Thus from
analyses of pseudotype assays with mixed trimers, it has
been concluded in one report that HIV-1 virion-cell fusion
requires only a single trimer [57]; by contrast, fitting the
same experimental data using alternative models with dif-
ferent underlying assumptions led to conclusions of
multi-trimer requirements: ~5, with a wide range of uncer-
tainty in one analysis [58], and ~8 with a range of 2 – 19
in another [59]. According to these multi-trimer mecha-
nisms, an infectious HIV-1 particle does not display a sig-
nificant excess of functional fusion units. For the
complementation analyses described herein where each
Env protomer contains a functional defect, it is likely that
the complementing trimers are less active than the fully
wild type counterparts; moreover as noted above, only a
subset of possible trimer forms are likely to be active. Thus
in the virus entry assay with complementing Envs, there
may be an insufficient number of functional fusion units
on most virions, resulting in a major reducton in the frac-
tion of virions with a functional fusion unit. Thus the
absence of detectable complementing activity in the virus
entry assay need not imply that virus-cell fuson proceeds
by a different mechanism than cell-cell fusion. However,
we acknowledge that the potential for mechanistic differ-
ences is not formally excluded, as emphasized by a recent
report arguing that HIV virion entry proceeds by endocy-
tosis and dynamin-dependent fusion out of the endo-
somes, with direct plasma membrane fusion failing to
promote content delivery [60].Retrovirology 2009, 6:75 http://www.retrovirology.com/content/6/1/75
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Given the experimental complexities, assessing the bio-
logical significance of subunit cooperativity for HIV entry
is a challenging problem. It is well known that there are
functional constraints on subunits within the trimer com-
pared to their monomeric counterparts. A particularly
striking example is the interaction of soluble CD4 (sCD4)
with gp120; the comparably high affinity of sCD4 for sol-
uble monomeric gp120 from primary and T cell line-
adapted HIV-1 isolates stands in marked contrast to the
relatively weak binding and neutralization activities of
sCD4 for native trimeric Env on the former compared to
the latter [61]. Cooperative subunit interactions, whereby
binding of gp120 to CD4 on one protomer in the trimer
initiates fusion-related conformational changes in the
other protomers, might thus enhance Env fusogenic activ-
ity, particularly toward target cells containing low densi-
ties of CD4 and coreceptor. Another consideration
involves the extensively studied phenomenon of epitope
masking within the HIV-1 Env trimer [62]. For example,
some highly conserved epitopes are freely accessible on
monomeric gp120 but are masked in the trimer prior to
CD4 binding; cooperative subunit interactions may facil-
itate exposure of such epitopes on subunits within the
trimer that have not yet engaged CD4. With questions
such as these in mind, the combination of detailed func-
tional and structural studies will potentially delineate the
molecular basis for subunit cooperativity within the
native HIV-1 Env trimer, and help define its biological sig-
nificance.
Conclusion
The data presented herein demonstrate that every subunit
within the Env trimer need not be competent for all criti-
cal activities. Cooperatvie cross-talk occurs between subu-
nits, thereby enabling adjacent protomers to complement
different functional defects. The diversity of defects that
can be complemented illustrates the general nature of
cooperative subunit interactions within the HIV-1 trimer.
Cooperativity may have important implications for Env
function and sensitivity to neutralization.
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